nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—SLC6A3—malignant glioma	0.635	1	CbGaD
Duloxetine—CYP1A2—Carmustine—malignant glioma	0.0708	1	CbGbCtD
Duloxetine—HTR2C—choroid plexus—malignant glioma	0.0193	0.184	CbGeAlD
Duloxetine—HTR2A—choroid plexus—malignant glioma	0.00967	0.0925	CbGeAlD
Duloxetine—SLC6A3—telencephalic ventricle—malignant glioma	0.00584	0.0559	CbGeAlD
Duloxetine—HTR2C—telencephalic ventricle—malignant glioma	0.00565	0.054	CbGeAlD
Duloxetine—HTR2A—cerebellar cortex—malignant glioma	0.00487	0.0466	CbGeAlD
Duloxetine—HTR2A—pons—malignant glioma	0.00344	0.0329	CbGeAlD
Duloxetine—HTR2A—vertebral column—malignant glioma	0.00342	0.0327	CbGeAlD
Duloxetine—NPY1R—telencephalon—malignant glioma	0.00334	0.0319	CbGeAlD
Duloxetine—Traumatic liver injury—Temozolomide—malignant glioma	0.00299	0.0247	CcSEcCtD
Duloxetine—HTR2A—telencephalic ventricle—malignant glioma	0.00283	0.0271	CbGeAlD
Duloxetine—HTR2A—pineal body—malignant glioma	0.00246	0.0235	CbGeAlD
Duloxetine—HTR6—telencephalon—malignant glioma	0.00235	0.0225	CbGeAlD
Duloxetine—NPY1R—central nervous system—malignant glioma	0.0019	0.0181	CbGeAlD
Duloxetine—SLC6A3—brainstem—malignant glioma	0.00158	0.0151	CbGeAlD
Duloxetine—Apathy—Temozolomide—malignant glioma	0.00156	0.0129	CcSEcCtD
Duloxetine—Flat affect—Temozolomide—malignant glioma	0.00155	0.0128	CcSEcCtD
Duloxetine—HTR2C—brainstem—malignant glioma	0.00153	0.0146	CbGeAlD
Duloxetine—HTR2A—endothelium—malignant glioma	0.00152	0.0145	CbGeAlD
Duloxetine—NPY1R—brain—malignant glioma	0.00151	0.0144	CbGeAlD
Duloxetine—Hepatotoxicity—Carmustine—malignant glioma	0.00149	0.0123	CcSEcCtD
Duloxetine—Extrapyramidal disorder—Temozolomide—malignant glioma	0.00148	0.0122	CcSEcCtD
Duloxetine—SLC6A4—brainstem—malignant glioma	0.00145	0.0139	CbGeAlD
Duloxetine—Hepatotoxicity—Temozolomide—malignant glioma	0.00144	0.0119	CcSEcCtD
Duloxetine—SLC6A3—telencephalon—malignant glioma	0.0014	0.0134	CbGeAlD
Duloxetine—HTR2A—blood vessel—malignant glioma	0.0014	0.0134	CbGeAlD
Duloxetine—Rigors—Temozolomide—malignant glioma	0.00137	0.0113	CcSEcCtD
Duloxetine—HTR2C—telencephalon—malignant glioma	0.00136	0.013	CbGeAlD
Duloxetine—Gamma-glutamyltransferase increased—Temozolomide—malignant glioma	0.00135	0.0112	CcSEcCtD
Duloxetine—Endocrine disorder—Temozolomide—malignant glioma	0.00134	0.0111	CcSEcCtD
Duloxetine—HTR6—central nervous system—malignant glioma	0.00133	0.0128	CbGeAlD
Duloxetine—Liver injury—Temozolomide—malignant glioma	0.00132	0.0109	CcSEcCtD
Duloxetine—Disturbance in attention—Temozolomide—malignant glioma	0.00129	0.0106	CcSEcCtD
Duloxetine—SLC6A4—telencephalon—malignant glioma	0.00129	0.0123	CbGeAlD
Duloxetine—SLC6A2—brainstem—malignant glioma	0.00128	0.0122	CbGeAlD
Duloxetine—Gait disturbance—Carmustine—malignant glioma	0.00118	0.00975	CcSEcCtD
Duloxetine—Hepatic enzyme increased—Temozolomide—malignant glioma	0.00118	0.00973	CcSEcCtD
Duloxetine—Coordination abnormal—Carmustine—malignant glioma	0.00117	0.00969	CcSEcCtD
Duloxetine—Neck pain—Carmustine—malignant glioma	0.00117	0.00964	CcSEcCtD
Duloxetine—Gait disturbance—Temozolomide—malignant glioma	0.00114	0.00943	CcSEcCtD
Duloxetine—Coordination abnormal—Temozolomide—malignant glioma	0.00114	0.00937	CcSEcCtD
Duloxetine—SLC6A2—telencephalon—malignant glioma	0.00113	0.0108	CbGeAlD
Duloxetine—Musculoskeletal pain—Temozolomide—malignant glioma	0.00113	0.00931	CcSEcCtD
Duloxetine—Phosphatase alkaline increased—Temozolomide—malignant glioma	0.00111	0.0092	CcSEcCtD
Duloxetine—Urinary incontinence—Carmustine—malignant glioma	0.00111	0.00919	CcSEcCtD
Duloxetine—Influenza like illness—Temozolomide—malignant glioma	0.00108	0.00894	CcSEcCtD
Duloxetine—Urinary incontinence—Temozolomide—malignant glioma	0.00108	0.00888	CcSEcCtD
Duloxetine—HTR2C—medulla oblongata—malignant glioma	0.00107	0.0102	CbGeAlD
Duloxetine—HTR6—brain—malignant glioma	0.00106	0.0101	CbGeAlD
Duloxetine—Dry eye—Temozolomide—malignant glioma	0.00103	0.0085	CcSEcCtD
Duloxetine—SLC6A3—midbrain—malignant glioma	0.00101	0.00964	CbGeAlD
Duloxetine—SLC6A3—spinal cord—malignant glioma	0.000983	0.00941	CbGeAlD
Duloxetine—HTR2C—midbrain—malignant glioma	0.000974	0.00932	CbGeAlD
Duloxetine—Phlebitis—Carmustine—malignant glioma	0.000972	0.00802	CcSEcCtD
Duloxetine—Diabetes mellitus—Carmustine—malignant glioma	0.000963	0.00795	CcSEcCtD
Duloxetine—HTR2C—spinal cord—malignant glioma	0.00095	0.00909	CbGeAlD
Duloxetine—Ear pain—Temozolomide—malignant glioma	0.000948	0.00783	CcSEcCtD
Duloxetine—Blood alkaline phosphatase increased—Temozolomide—malignant glioma	0.00093	0.00768	CcSEcCtD
Duloxetine—SLC6A4—midbrain—malignant glioma	0.000924	0.00883	CbGeAlD
Duloxetine—Gastroenteritis—Temozolomide—malignant glioma	0.000913	0.00754	CcSEcCtD
Duloxetine—SLC6A4—spinal cord—malignant glioma	0.000901	0.00862	CbGeAlD
Duloxetine—Hepatic failure—Temozolomide—malignant glioma	0.0009	0.00743	CcSEcCtD
Duloxetine—SLC6A2—medulla oblongata—malignant glioma	0.00089	0.00851	CbGeAlD
Duloxetine—Hot flush—Temozolomide—malignant glioma	0.000865	0.00714	CcSEcCtD
Duloxetine—Menopausal symptoms—Temozolomide—malignant glioma	0.000858	0.00708	CcSEcCtD
Duloxetine—Dermatitis exfoliative—Temozolomide—malignant glioma	0.000858	0.00708	CcSEcCtD
Duloxetine—Thirst—Temozolomide—malignant glioma	0.00085	0.00702	CcSEcCtD
Duloxetine—Hyponatraemia—Carmustine—malignant glioma	0.000841	0.00694	CcSEcCtD
Duloxetine—Diplopia—Carmustine—malignant glioma	0.000837	0.00691	CcSEcCtD
Duloxetine—Gastrointestinal haemorrhage—Carmustine—malignant glioma	0.000837	0.00691	CcSEcCtD
Duloxetine—HTR2A—embryo—malignant glioma	0.000837	0.008	CbGeAlD
Duloxetine—Diplopia—Temozolomide—malignant glioma	0.000809	0.00668	CcSEcCtD
Duloxetine—Face oedema—Carmustine—malignant glioma	0.000808	0.00667	CcSEcCtD
Duloxetine—SLC6A3—central nervous system—malignant glioma	0.000798	0.00763	CbGeAlD
Duloxetine—Affect lability—Temozolomide—malignant glioma	0.000796	0.00657	CcSEcCtD
Duloxetine—Ataxia—Carmustine—malignant glioma	0.000787	0.0065	CcSEcCtD
Duloxetine—Face oedema—Temozolomide—malignant glioma	0.000781	0.00645	CcSEcCtD
Duloxetine—SLC6A3—cerebellum—malignant glioma	0.00078	0.00746	CbGeAlD
Duloxetine—Liver function test abnormal—Carmustine—malignant glioma	0.000773	0.00638	CcSEcCtD
Duloxetine—HTR2C—central nervous system—malignant glioma	0.000771	0.00738	CbGeAlD
Duloxetine—HTR2A—brainstem—malignant glioma	0.000767	0.00733	CbGeAlD
Duloxetine—Mood swings—Temozolomide—malignant glioma	0.000767	0.00633	CcSEcCtD
Duloxetine—Ataxia—Temozolomide—malignant glioma	0.000761	0.00628	CcSEcCtD
Duloxetine—Dehydration—Temozolomide—malignant glioma	0.000753	0.00621	CcSEcCtD
Duloxetine—HTR2A—retina—malignant glioma	0.00074	0.00708	CbGeAlD
Duloxetine—Muscular weakness—Carmustine—malignant glioma	0.000739	0.0061	CcSEcCtD
Duloxetine—Breast disorder—Temozolomide—malignant glioma	0.000731	0.00604	CcSEcCtD
Duloxetine—SLC6A4—central nervous system—malignant glioma	0.000731	0.00699	CbGeAlD
Duloxetine—Aspartate aminotransferase increased—Temozolomide—malignant glioma	0.000729	0.00601	CcSEcCtD
Duloxetine—Dysphagia—Carmustine—malignant glioma	0.000724	0.00597	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Temozolomide—malignant glioma	0.000714	0.00589	CcSEcCtD
Duloxetine—Muscular weakness—Temozolomide—malignant glioma	0.000714	0.00589	CcSEcCtD
Duloxetine—Dysphagia—Temozolomide—malignant glioma	0.000699	0.00577	CcSEcCtD
Duloxetine—CYP2D6—brainstem—malignant glioma	0.000699	0.00668	CbGeAlD
Duloxetine—Sweating increased—Temozolomide—malignant glioma	0.000681	0.00562	CcSEcCtD
Duloxetine—HTR2A—telencephalon—malignant glioma	0.000681	0.00651	CbGeAlD
Duloxetine—Dysuria—Temozolomide—malignant glioma	0.000654	0.0054	CcSEcCtD
Duloxetine—Hyperglycaemia—Carmustine—malignant glioma	0.000653	0.00539	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Temozolomide—malignant glioma	0.00065	0.00536	CcSEcCtD
Duloxetine—Pollakiuria—Temozolomide—malignant glioma	0.000646	0.00533	CcSEcCtD
Duloxetine—Erectile dysfunction—Temozolomide—malignant glioma	0.000644	0.00532	CcSEcCtD
Duloxetine—SLC6A2—central nervous system—malignant glioma	0.000644	0.00616	CbGeAlD
Duloxetine—Photosensitivity reaction—Temozolomide—malignant glioma	0.000638	0.00527	CcSEcCtD
Duloxetine—Weight increased—Temozolomide—malignant glioma	0.000636	0.00525	CcSEcCtD
Duloxetine—Renal failure—Carmustine—malignant glioma	0.000634	0.00524	CcSEcCtD
Duloxetine—SLC6A3—brain—malignant glioma	0.000633	0.00606	CbGeAlD
Duloxetine—Weight decreased—Temozolomide—malignant glioma	0.000633	0.00522	CcSEcCtD
Duloxetine—Hyperglycaemia—Temozolomide—malignant glioma	0.000631	0.00521	CcSEcCtD
Duloxetine—Stomatitis—Carmustine—malignant glioma	0.000629	0.00519	CcSEcCtD
Duloxetine—Urinary tract infection—Carmustine—malignant glioma	0.000627	0.00518	CcSEcCtD
Duloxetine—Infestation NOS—Temozolomide—malignant glioma	0.000624	0.00515	CcSEcCtD
Duloxetine—Infestation—Temozolomide—malignant glioma	0.000624	0.00515	CcSEcCtD
Duloxetine—CYP2D6—telencephalon—malignant glioma	0.00062	0.00593	CbGeAlD
Duloxetine—Fluoxetine—CYP2B6—malignant glioma	0.000619	0.646	CrCbGaD
Duloxetine—Stevens-Johnson syndrome—Temozolomide—malignant glioma	0.000618	0.0051	CcSEcCtD
Duloxetine—HTR2C—brain—malignant glioma	0.000612	0.00586	CbGeAlD
Duloxetine—Stomatitis—Temozolomide—malignant glioma	0.000608	0.00502	CcSEcCtD
Duloxetine—Urinary tract infection—Temozolomide—malignant glioma	0.000606	0.005	CcSEcCtD
Duloxetine—Hepatobiliary disease—Temozolomide—malignant glioma	0.00059	0.00487	CcSEcCtD
Duloxetine—Haemoglobin—Carmustine—malignant glioma	0.000582	0.00481	CcSEcCtD
Duloxetine—SLC6A4—brain—malignant glioma	0.00058	0.00555	CbGeAlD
Duloxetine—Haemorrhage—Carmustine—malignant glioma	0.000579	0.00478	CcSEcCtD
Duloxetine—Hallucination—Carmustine—malignant glioma	0.000576	0.00476	CcSEcCtD
Duloxetine—Hypoaesthesia—Carmustine—malignant glioma	0.000576	0.00476	CcSEcCtD
Duloxetine—Oedema peripheral—Carmustine—malignant glioma	0.000571	0.00471	CcSEcCtD
Duloxetine—Connective tissue disorder—Carmustine—malignant glioma	0.000569	0.0047	CcSEcCtD
Duloxetine—Haemoglobin—Temozolomide—malignant glioma	0.000563	0.00464	CcSEcCtD
Duloxetine—Haemorrhage—Temozolomide—malignant glioma	0.00056	0.00462	CcSEcCtD
Duloxetine—Hepatitis—Temozolomide—malignant glioma	0.00056	0.00462	CcSEcCtD
Duloxetine—Visual impairment—Carmustine—malignant glioma	0.000558	0.00461	CcSEcCtD
Duloxetine—Hallucination—Temozolomide—malignant glioma	0.000557	0.0046	CcSEcCtD
Duloxetine—Hypoaesthesia—Temozolomide—malignant glioma	0.000557	0.0046	CcSEcCtD
Duloxetine—Pharyngitis—Temozolomide—malignant glioma	0.000556	0.00459	CcSEcCtD
Duloxetine—Urinary tract disorder—Temozolomide—malignant glioma	0.000553	0.00456	CcSEcCtD
Duloxetine—Oedema peripheral—Temozolomide—malignant glioma	0.000551	0.00455	CcSEcCtD
Duloxetine—Connective tissue disorder—Temozolomide—malignant glioma	0.00055	0.00454	CcSEcCtD
Duloxetine—Urethral disorder—Temozolomide—malignant glioma	0.000549	0.00453	CcSEcCtD
Duloxetine—Eye disorder—Carmustine—malignant glioma	0.000541	0.00447	CcSEcCtD
Duloxetine—Visual impairment—Temozolomide—malignant glioma	0.000539	0.00445	CcSEcCtD
Duloxetine—Flushing—Carmustine—malignant glioma	0.000538	0.00444	CcSEcCtD
Duloxetine—HTR2A—medulla oblongata—malignant glioma	0.000535	0.00511	CbGeAlD
Duloxetine—Erythema multiforme—Temozolomide—malignant glioma	0.000529	0.00437	CcSEcCtD
Duloxetine—Eye disorder—Temozolomide—malignant glioma	0.000523	0.00432	CcSEcCtD
Duloxetine—Tinnitus—Temozolomide—malignant glioma	0.000522	0.00431	CcSEcCtD
Duloxetine—Cardiac disorder—Temozolomide—malignant glioma	0.00052	0.00429	CcSEcCtD
Duloxetine—Flushing—Temozolomide—malignant glioma	0.00052	0.00429	CcSEcCtD
Duloxetine—Arrhythmia—Carmustine—malignant glioma	0.000517	0.00427	CcSEcCtD
Duloxetine—Alopecia—Carmustine—malignant glioma	0.000512	0.00422	CcSEcCtD
Duloxetine—SLC6A2—brain—malignant glioma	0.000511	0.00489	CbGeAlD
Duloxetine—Angiopathy—Temozolomide—malignant glioma	0.000508	0.00419	CcSEcCtD
Duloxetine—Mental disorder—Carmustine—malignant glioma	0.000507	0.00419	CcSEcCtD
Duloxetine—Immune system disorder—Temozolomide—malignant glioma	0.000506	0.00417	CcSEcCtD
Duloxetine—Mediastinal disorder—Temozolomide—malignant glioma	0.000505	0.00416	CcSEcCtD
Duloxetine—Erythema—Carmustine—malignant glioma	0.000504	0.00416	CcSEcCtD
Duloxetine—Malnutrition—Carmustine—malignant glioma	0.000504	0.00416	CcSEcCtD
Duloxetine—Chills—Temozolomide—malignant glioma	0.000502	0.00415	CcSEcCtD
Duloxetine—Alopecia—Temozolomide—malignant glioma	0.000495	0.00408	CcSEcCtD
Duloxetine—Mental disorder—Temozolomide—malignant glioma	0.00049	0.00405	CcSEcCtD
Duloxetine—HTR2A—midbrain—malignant glioma	0.000489	0.00467	CbGeAlD
Duloxetine—Back pain—Carmustine—malignant glioma	0.000488	0.00403	CcSEcCtD
Duloxetine—Malnutrition—Temozolomide—malignant glioma	0.000487	0.00402	CcSEcCtD
Duloxetine—Erythema—Temozolomide—malignant glioma	0.000487	0.00402	CcSEcCtD
Duloxetine—Dysgeusia—Temozolomide—malignant glioma	0.000477	0.00394	CcSEcCtD
Duloxetine—HTR2A—spinal cord—malignant glioma	0.000477	0.00456	CbGeAlD
Duloxetine—Vision blurred—Carmustine—malignant glioma	0.000475	0.00392	CcSEcCtD
Duloxetine—Tremor—Carmustine—malignant glioma	0.000472	0.0039	CcSEcCtD
Duloxetine—Back pain—Temozolomide—malignant glioma	0.000471	0.00389	CcSEcCtD
Duloxetine—Anaemia—Carmustine—malignant glioma	0.000466	0.00385	CcSEcCtD
Duloxetine—Agitation—Carmustine—malignant glioma	0.000463	0.00382	CcSEcCtD
Duloxetine—Vision blurred—Temozolomide—malignant glioma	0.000459	0.00379	CcSEcCtD
Duloxetine—Tremor—Temozolomide—malignant glioma	0.000457	0.00377	CcSEcCtD
Duloxetine—Ill-defined disorder—Temozolomide—malignant glioma	0.000452	0.00373	CcSEcCtD
Duloxetine—Leukopenia—Carmustine—malignant glioma	0.000451	0.00373	CcSEcCtD
Duloxetine—Anaemia—Temozolomide—malignant glioma	0.00045	0.00372	CcSEcCtD
Duloxetine—Agitation—Temozolomide—malignant glioma	0.000448	0.0037	CcSEcCtD
Duloxetine—Angioedema—Temozolomide—malignant glioma	0.000445	0.00368	CcSEcCtD
Duloxetine—Malaise—Temozolomide—malignant glioma	0.000439	0.00363	CcSEcCtD
Duloxetine—Vertigo—Temozolomide—malignant glioma	0.000438	0.00361	CcSEcCtD
Duloxetine—Convulsion—Carmustine—malignant glioma	0.000437	0.00361	CcSEcCtD
Duloxetine—Leukopenia—Temozolomide—malignant glioma	0.000436	0.0036	CcSEcCtD
Duloxetine—Hypertension—Carmustine—malignant glioma	0.000435	0.00359	CcSEcCtD
Duloxetine—Palpitations—Temozolomide—malignant glioma	0.000431	0.00355	CcSEcCtD
Duloxetine—Chest pain—Carmustine—malignant glioma	0.000429	0.00354	CcSEcCtD
Duloxetine—Myalgia—Carmustine—malignant glioma	0.000429	0.00354	CcSEcCtD
Duloxetine—Anxiety—Carmustine—malignant glioma	0.000428	0.00353	CcSEcCtD
Duloxetine—Cough—Temozolomide—malignant glioma	0.000425	0.00351	CcSEcCtD
Duloxetine—Convulsion—Temozolomide—malignant glioma	0.000422	0.00348	CcSEcCtD
Duloxetine—Hypertension—Temozolomide—malignant glioma	0.000421	0.00347	CcSEcCtD
Duloxetine—Confusional state—Carmustine—malignant glioma	0.000415	0.00342	CcSEcCtD
Duloxetine—Myalgia—Temozolomide—malignant glioma	0.000415	0.00342	CcSEcCtD
Duloxetine—Arthralgia—Temozolomide—malignant glioma	0.000415	0.00342	CcSEcCtD
Duloxetine—Anxiety—Temozolomide—malignant glioma	0.000413	0.00341	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—malignant glioma	0.000412	0.0034	CcSEcCtD
Duloxetine—Oedema—Carmustine—malignant glioma	0.000412	0.0034	CcSEcCtD
Duloxetine—Discomfort—Temozolomide—malignant glioma	0.00041	0.00338	CcSEcCtD
Duloxetine—Infection—Carmustine—malignant glioma	0.000409	0.00337	CcSEcCtD
Duloxetine—Dry mouth—Temozolomide—malignant glioma	0.000406	0.00335	CcSEcCtD
Duloxetine—Thrombocytopenia—Carmustine—malignant glioma	0.000403	0.00333	CcSEcCtD
Duloxetine—Tachycardia—Carmustine—malignant glioma	0.000402	0.00332	CcSEcCtD
Duloxetine—Confusional state—Temozolomide—malignant glioma	0.000401	0.00331	CcSEcCtD
Duloxetine—Oedema—Temozolomide—malignant glioma	0.000398	0.00328	CcSEcCtD
Duloxetine—Anaphylactic shock—Temozolomide—malignant glioma	0.000398	0.00328	CcSEcCtD
Duloxetine—Infection—Temozolomide—malignant glioma	0.000395	0.00326	CcSEcCtD
Duloxetine—Anorexia—Carmustine—malignant glioma	0.000392	0.00324	CcSEcCtD
Duloxetine—Nervous system disorder—Temozolomide—malignant glioma	0.00039	0.00322	CcSEcCtD
Duloxetine—Thrombocytopenia—Temozolomide—malignant glioma	0.000389	0.00321	CcSEcCtD
Duloxetine—HTR2A—central nervous system—malignant glioma	0.000387	0.0037	CbGeAlD
Duloxetine—Skin disorder—Temozolomide—malignant glioma	0.000386	0.00319	CcSEcCtD
Duloxetine—Hyperhidrosis—Temozolomide—malignant glioma	0.000384	0.00317	CcSEcCtD
Duloxetine—Anorexia—Temozolomide—malignant glioma	0.000379	0.00313	CcSEcCtD
Duloxetine—HTR2A—cerebellum—malignant glioma	0.000378	0.00362	CbGeAlD
Duloxetine—Musculoskeletal discomfort—Carmustine—malignant glioma	0.000375	0.00309	CcSEcCtD
Duloxetine—Insomnia—Carmustine—malignant glioma	0.000372	0.00307	CcSEcCtD
Duloxetine—Paraesthesia—Carmustine—malignant glioma	0.00037	0.00305	CcSEcCtD
Duloxetine—Somnolence—Carmustine—malignant glioma	0.000366	0.00302	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Temozolomide—malignant glioma	0.000362	0.00299	CcSEcCtD
Duloxetine—Insomnia—Temozolomide—malignant glioma	0.00036	0.00297	CcSEcCtD
Duloxetine—Decreased appetite—Carmustine—malignant glioma	0.000358	0.00295	CcSEcCtD
Duloxetine—Paraesthesia—Temozolomide—malignant glioma	0.000357	0.00295	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Carmustine—malignant glioma	0.000355	0.00293	CcSEcCtD
Duloxetine—Somnolence—Temozolomide—malignant glioma	0.000354	0.00292	CcSEcCtD
Duloxetine—CYP2D6—central nervous system—malignant glioma	0.000352	0.00337	CbGeAlD
Duloxetine—Constipation—Carmustine—malignant glioma	0.000352	0.0029	CcSEcCtD
Duloxetine—Pain—Carmustine—malignant glioma	0.000352	0.0029	CcSEcCtD
Duloxetine—Dyspepsia—Temozolomide—malignant glioma	0.00035	0.00289	CcSEcCtD
Duloxetine—Decreased appetite—Temozolomide—malignant glioma	0.000346	0.00285	CcSEcCtD
Duloxetine—CYP2D6—cerebellum—malignant glioma	0.000344	0.00329	CbGeAlD
Duloxetine—Gastrointestinal disorder—Temozolomide—malignant glioma	0.000343	0.00283	CcSEcCtD
Duloxetine—Fatigue—Temozolomide—malignant glioma	0.000343	0.00283	CcSEcCtD
Duloxetine—Pain—Temozolomide—malignant glioma	0.00034	0.00281	CcSEcCtD
Duloxetine—Constipation—Temozolomide—malignant glioma	0.00034	0.00281	CcSEcCtD
Duloxetine—Feeling abnormal—Carmustine—malignant glioma	0.000339	0.0028	CcSEcCtD
Duloxetine—Atomoxetine—SLC6A3—malignant glioma	0.000339	0.354	CrCbGaD
Duloxetine—Gastrointestinal pain—Carmustine—malignant glioma	0.000337	0.00278	CcSEcCtD
Duloxetine—Feeling abnormal—Temozolomide—malignant glioma	0.000328	0.0027	CcSEcCtD
Duloxetine—Body temperature increased—Carmustine—malignant glioma	0.000325	0.00269	CcSEcCtD
Duloxetine—Abdominal pain—Carmustine—malignant glioma	0.000325	0.00269	CcSEcCtD
Duloxetine—Gastrointestinal pain—Temozolomide—malignant glioma	0.000325	0.00268	CcSEcCtD
Duloxetine—Urticaria—Temozolomide—malignant glioma	0.000316	0.00261	CcSEcCtD
Duloxetine—Abdominal pain—Temozolomide—malignant glioma	0.000314	0.00259	CcSEcCtD
Duloxetine—Body temperature increased—Temozolomide—malignant glioma	0.000314	0.00259	CcSEcCtD
Duloxetine—HTR2A—brain—malignant glioma	0.000307	0.00294	CbGeAlD
Duloxetine—Hypersensitivity—Carmustine—malignant glioma	0.000303	0.0025	CcSEcCtD
Duloxetine—Asthenia—Carmustine—malignant glioma	0.000295	0.00244	CcSEcCtD
Duloxetine—Hypersensitivity—Temozolomide—malignant glioma	0.000293	0.00242	CcSEcCtD
Duloxetine—Asthenia—Temozolomide—malignant glioma	0.000285	0.00236	CcSEcCtD
Duloxetine—Diarrhoea—Carmustine—malignant glioma	0.000282	0.00232	CcSEcCtD
Duloxetine—Pruritus—Temozolomide—malignant glioma	0.000281	0.00232	CcSEcCtD
Duloxetine—CYP2D6—brain—malignant glioma	0.00028	0.00268	CbGeAlD
Duloxetine—Dizziness—Carmustine—malignant glioma	0.000272	0.00225	CcSEcCtD
Duloxetine—Diarrhoea—Temozolomide—malignant glioma	0.000272	0.00225	CcSEcCtD
Duloxetine—Dizziness—Temozolomide—malignant glioma	0.000263	0.00217	CcSEcCtD
Duloxetine—Vomiting—Carmustine—malignant glioma	0.000262	0.00216	CcSEcCtD
Duloxetine—Rash—Carmustine—malignant glioma	0.000259	0.00214	CcSEcCtD
Duloxetine—Dermatitis—Carmustine—malignant glioma	0.000259	0.00214	CcSEcCtD
Duloxetine—Headache—Carmustine—malignant glioma	0.000258	0.00213	CcSEcCtD
Duloxetine—Vomiting—Temozolomide—malignant glioma	0.000253	0.00209	CcSEcCtD
Duloxetine—Rash—Temozolomide—malignant glioma	0.000251	0.00207	CcSEcCtD
Duloxetine—Dermatitis—Temozolomide—malignant glioma	0.000251	0.00207	CcSEcCtD
Duloxetine—Headache—Temozolomide—malignant glioma	0.000249	0.00206	CcSEcCtD
Duloxetine—Nausea—Carmustine—malignant glioma	0.000244	0.00202	CcSEcCtD
Duloxetine—Nausea—Temozolomide—malignant glioma	0.000236	0.00195	CcSEcCtD
Duloxetine—HTR2C—Signaling Pathways—NOTCH3—malignant glioma	1.84e-05	0.000271	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HES1—malignant glioma	1.84e-05	0.00027	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NCOR1—malignant glioma	1.83e-05	0.000269	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FBXW7—malignant glioma	1.81e-05	0.000266	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—RAF1—malignant glioma	1.8e-05	0.000265	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—malignant glioma	1.78e-05	0.000262	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BDKRB2—malignant glioma	1.78e-05	0.000261	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—F2—malignant glioma	1.77e-05	0.00026	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CB—malignant glioma	1.76e-05	0.000259	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PDGFRA—malignant glioma	1.75e-05	0.000257	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PIK3CA—malignant glioma	1.72e-05	0.000253	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT2—malignant glioma	1.71e-05	0.000251	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—H3F3A—malignant glioma	1.7e-05	0.00025	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SPP1—malignant glioma	1.7e-05	0.00025	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—IDH1—malignant glioma	1.7e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CG—malignant glioma	1.69e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL8—malignant glioma	1.69e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—F2—malignant glioma	1.69e-05	0.000249	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCR3—malignant glioma	1.69e-05	0.000248	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—IDH2—malignant glioma	1.67e-05	0.000246	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—malignant glioma	1.66e-05	0.000244	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PTPN11—malignant glioma	1.66e-05	0.000244	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH2—malignant glioma	1.65e-05	0.000243	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SPHK1—malignant glioma	1.64e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—YWHAE—malignant glioma	1.64e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK2—malignant glioma	1.64e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CD—malignant glioma	1.64e-05	0.000241	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FLT1—malignant glioma	1.63e-05	0.00024	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—DUSP6—malignant glioma	1.63e-05	0.000239	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CG—malignant glioma	1.62e-05	0.000238	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—malignant glioma	1.62e-05	0.000238	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KNG1—malignant glioma	1.62e-05	0.000238	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TERT—malignant glioma	1.61e-05	0.000237	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2C18—malignant glioma	1.61e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—JAG1—malignant glioma	1.61e-05	0.000236	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH3—malignant glioma	1.6e-05	0.000235	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—malignant glioma	1.58e-05	0.000232	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FBXW7—malignant glioma	1.57e-05	0.000231	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PDGFB—malignant glioma	1.57e-05	0.000231	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2B6—malignant glioma	1.57e-05	0.000231	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGFR1—malignant glioma	1.56e-05	0.00023	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT2—malignant glioma	1.55e-05	0.000228	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BDKRB2—malignant glioma	1.54e-05	0.000227	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—HIF1A—malignant glioma	1.54e-05	0.000226	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NTRK1—malignant glioma	1.54e-05	0.000226	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—F2—malignant glioma	1.54e-05	0.000226	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CAV1—malignant glioma	1.49e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CD—malignant glioma	1.49e-05	0.000219	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT2—malignant glioma	1.48e-05	0.000218	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KDR—malignant glioma	1.47e-05	0.000217	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CG—malignant glioma	1.47e-05	0.000216	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PTPN11—malignant glioma	1.44e-05	0.000212	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—IDH1—malignant glioma	1.44e-05	0.000211	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH2—malignant glioma	1.43e-05	0.000211	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP3—malignant glioma	1.43e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CB—malignant glioma	1.43e-05	0.00021	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CD—malignant glioma	1.42e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN2B—malignant glioma	1.42e-05	0.000209	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—F2—malignant glioma	1.42e-05	0.000208	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FN1—malignant glioma	1.42e-05	0.000208	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—AKT1—malignant glioma	1.4e-05	0.000206	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KNG1—malignant glioma	1.4e-05	0.000206	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BAD—malignant glioma	1.4e-05	0.000206	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SPHK1—malignant glioma	1.39e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NOTCH1—malignant glioma	1.39e-05	0.000204	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTK2—malignant glioma	1.38e-05	0.000203	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL8—malignant glioma	1.37e-05	0.000202	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2C18—malignant glioma	1.36e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CD80—malignant glioma	1.36e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CG—malignant glioma	1.36e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—APC—malignant glioma	1.36e-05	0.0002	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HES1—malignant glioma	1.35e-05	0.000199	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NCOR1—malignant glioma	1.35e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT2—malignant glioma	1.34e-05	0.000198	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGF—malignant glioma	1.34e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NTRK1—malignant glioma	1.34e-05	0.000197	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTPN11—malignant glioma	1.33e-05	0.000196	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—RAF1—malignant glioma	1.33e-05	0.000195	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—malignant glioma	1.31e-05	0.000193	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTT1—malignant glioma	1.3e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CB—malignant glioma	1.3e-05	0.000191	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CD—malignant glioma	1.29e-05	0.00019	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDGFRA—malignant glioma	1.29e-05	0.000189	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—malignant glioma	1.29e-05	0.000189	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—BRAF—malignant glioma	1.28e-05	0.000188	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SPP1—malignant glioma	1.25e-05	0.000184	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL8—malignant glioma	1.25e-05	0.000183	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP3—malignant glioma	1.24e-05	0.000183	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT2—malignant glioma	1.24e-05	0.000183	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CB—malignant glioma	1.24e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—EGFR—malignant glioma	1.24e-05	0.000182	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN2B—malignant glioma	1.23e-05	0.000181	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS1—malignant glioma	1.22e-05	0.000179	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTK2—malignant glioma	1.2e-05	0.000176	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CD—malignant glioma	1.19e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL8—malignant glioma	1.19e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—malignant glioma	1.19e-05	0.000175	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TERT—malignant glioma	1.19e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—PIK3CA—malignant glioma	1.18e-05	0.000174	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HES1—malignant glioma	1.18e-05	0.000173	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CG—malignant glioma	1.17e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NCOR1—malignant glioma	1.17e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—KRAS—malignant glioma	1.17e-05	0.000172	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PDGFB—malignant glioma	1.16e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—RAF1—malignant glioma	1.15e-05	0.00017	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGFR1—malignant glioma	1.15e-05	0.000169	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—FGF2—malignant glioma	1.14e-05	0.000168	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—malignant glioma	1.14e-05	0.000167	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—HIF1A—malignant glioma	1.13e-05	0.000167	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—BCHE—malignant glioma	1.13e-05	0.000167	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—malignant glioma	1.13e-05	0.000166	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CB—malignant glioma	1.13e-05	0.000166	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—SLC5A5—malignant glioma	1.12e-05	0.000165	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFRA—malignant glioma	1.12e-05	0.000165	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTT1—malignant glioma	1.1e-05	0.000162	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CAV1—malignant glioma	1.1e-05	0.000161	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SPP1—malignant glioma	1.09e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KDR—malignant glioma	1.09e-05	0.00016	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL8—malignant glioma	1.08e-05	0.000159	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—PIK3CA—malignant glioma	1.07e-05	0.000158	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MDM2—malignant glioma	1.07e-05	0.000157	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RAF1—malignant glioma	1.07e-05	0.000157	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—ERBB2—malignant glioma	1.05e-05	0.000155	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FN1—malignant glioma	1.04e-05	0.000154	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2—malignant glioma	1.04e-05	0.000154	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CB—malignant glioma	1.04e-05	0.000153	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—malignant glioma	1.03e-05	0.000152	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS1—malignant glioma	1.03e-05	0.000152	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BAD—malignant glioma	1.03e-05	0.000152	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TERT—malignant glioma	1.03e-05	0.000151	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CD—malignant glioma	1.03e-05	0.000151	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NOTCH1—malignant glioma	1.02e-05	0.00015	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PDGFB—malignant glioma	1.01e-05	0.000148	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CD80—malignant glioma	1e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGFR1—malignant glioma	1e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CG—malignant glioma	1e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—APC—malignant glioma	1e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL8—malignant glioma	1e-05	0.000147	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGF—malignant glioma	9.88e-06	0.000145	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—HIF1A—malignant glioma	9.85e-06	0.000145	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTPN11—malignant glioma	9.82e-06	0.000144	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—AKT1—malignant glioma	9.66e-06	0.000142	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—BCHE—malignant glioma	9.6e-06	0.000141	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CASP3—malignant glioma	9.57e-06	0.000141	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—malignant glioma	9.55e-06	0.00014	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CAV1—malignant glioma	9.53e-06	0.00014	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—SLC5A5—malignant glioma	9.49e-06	0.000139	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KDR—malignant glioma	9.42e-06	0.000139	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—BRAF—malignant glioma	9.4e-06	0.000138	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT2—malignant glioma	9.15e-06	0.000134	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—EGFR—malignant glioma	9.11e-06	0.000134	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FN1—malignant glioma	9.07e-06	0.000133	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2—malignant glioma	9.07e-06	0.000133	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MMP9—malignant glioma	9.04e-06	0.000133	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GSTP1—malignant glioma	9.02e-06	0.000133	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—malignant glioma	8.99e-06	0.000132	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CB—malignant glioma	8.97e-06	0.000132	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BAD—malignant glioma	8.96e-06	0.000132	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—malignant glioma	8.89e-06	0.000131	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NOTCH1—malignant glioma	8.88e-06	0.00013	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CD—malignant glioma	8.79e-06	0.000129	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAT—malignant glioma	8.78e-06	0.000129	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—AKT1—malignant glioma	8.77e-06	0.000129	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—PIK3CA—malignant glioma	8.7e-06	0.000128	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CD80—malignant glioma	8.7e-06	0.000128	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CG—malignant glioma	8.68e-06	0.000128	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—APC—malignant glioma	8.68e-06	0.000128	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—KRAS—malignant glioma	8.6e-06	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGF—malignant glioma	8.58e-06	0.000126	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTPN11—malignant glioma	8.53e-06	0.000125	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—FGF2—malignant glioma	8.41e-06	0.000124	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—NCOR1—malignant glioma	8.29e-06	0.000122	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—BRAF—malignant glioma	8.16e-06	0.00012	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—VEGFA—malignant glioma	8.12e-06	0.000119	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—STAT3—malignant glioma	8.04e-06	0.000118	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT2—malignant glioma	7.94e-06	0.000117	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—EGFR—malignant glioma	7.91e-06	0.000116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—PIK3CA—malignant glioma	7.9e-06	0.000116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MDM2—malignant glioma	7.87e-06	0.000116	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RAF1—malignant glioma	7.85e-06	0.000115	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—ERBB2—malignant glioma	7.76e-06	0.000114	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—malignant glioma	7.75e-06	0.000114	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CB—malignant glioma	7.66e-06	0.000113	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GSTP1—malignant glioma	7.64e-06	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CD—malignant glioma	7.63e-06	0.000112	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—PIK3CA—malignant glioma	7.56e-06	0.000111	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—KRAS—malignant glioma	7.47e-06	0.00011	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—MYC—malignant glioma	7.47e-06	0.00011	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAT—malignant glioma	7.44e-06	0.000109	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL8—malignant glioma	7.36e-06	0.000108	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—FGF2—malignant glioma	7.31e-06	0.000107	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—EGFR—malignant glioma	7.31e-06	0.000107	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—AKT1—malignant glioma	7.11e-06	0.000105	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CASP3—malignant glioma	7.05e-06	0.000104	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—malignant glioma	7.04e-06	0.000103	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—NCOR1—malignant glioma	7.02e-06	0.000103	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—KRAS—malignant glioma	6.9e-06	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—PIK3CA—malignant glioma	6.86e-06	0.000101	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MDM2—malignant glioma	6.84e-06	0.0001	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RAF1—malignant glioma	6.81e-06	0.0001	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CAV1—malignant glioma	6.76e-06	9.93e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—ERBB2—malignant glioma	6.74e-06	9.91e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MMP9—malignant glioma	6.66e-06	9.79e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CB—malignant glioma	6.65e-06	9.78e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—malignant glioma	6.62e-06	9.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—AKT1—malignant glioma	6.46e-06	9.49e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL8—malignant glioma	6.39e-06	9.4e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PIK3CA—malignant glioma	6.34e-06	9.32e-05	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—AKT1—malignant glioma	6.18e-06	9.08e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CG—malignant glioma	6.15e-06	9.05e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—malignant glioma	6.13e-06	9.02e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CASP3—malignant glioma	6.12e-06	8.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—malignant glioma	6.11e-06	8.98e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—VEGFA—malignant glioma	5.98e-06	8.79e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PPARG—malignant glioma	5.94e-06	8.73e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—STAT3—malignant glioma	5.92e-06	8.7e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MMP9—malignant glioma	5.78e-06	8.5e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—malignant glioma	5.75e-06	8.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CAV1—malignant glioma	5.72e-06	8.41e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—AKT1—malignant glioma	5.61e-06	8.24e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—MYC—malignant glioma	5.5e-06	8.08e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PIK3CA—malignant glioma	5.47e-06	8.04e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CD—malignant glioma	5.41e-06	7.95e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—EGFR—malignant glioma	5.38e-06	7.91e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CG—malignant glioma	5.21e-06	7.66e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—VEGFA—malignant glioma	5.19e-06	7.63e-05	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—AKT1—malignant glioma	5.18e-06	7.61e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—STAT3—malignant glioma	5.14e-06	7.56e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—KRAS—malignant glioma	5.08e-06	7.47e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PPARG—malignant glioma	5.03e-06	7.4e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—MYC—malignant glioma	4.78e-06	7.02e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CB—malignant glioma	4.72e-06	6.93e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTGS2—malignant glioma	4.67e-06	6.87e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—EGFR—malignant glioma	4.67e-06	6.87e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PIK3CA—malignant glioma	4.67e-06	6.86e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CD—malignant glioma	4.58e-06	6.74e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—malignant glioma	4.52e-06	6.64e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—KRAS—malignant glioma	4.41e-06	6.49e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—malignant glioma	4.08e-06	5.99e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PIK3CA—malignant glioma	4.06e-06	5.96e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CB—malignant glioma	4e-06	5.87e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTGS2—malignant glioma	3.96e-06	5.82e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—malignant glioma	3.92e-06	5.77e-05	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—AKT1—malignant glioma	3.81e-06	5.61e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—malignant glioma	3.45e-06	5.07e-05	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—AKT1—malignant glioma	3.31e-06	4.87e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PIK3CA—malignant glioma	2.87e-06	4.23e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PIK3CA—malignant glioma	2.44e-06	3.58e-05	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKT1—malignant glioma	2.35e-06	3.45e-05	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKT1—malignant glioma	1.99e-06	2.92e-05	CbGpPWpGaD
